ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: LB05 • ACR Convergence 2025

    ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling

    yujie cai, Nanfang hospital, Guangzhou, China (People's Republic)

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…
  • Abstract Number: LB15 • ACR Convergence 2025

    Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial

    Claire Immediato Daien1, Jean-Pierre Hellier2, Zübeyir Salis3, Gaël Mouterde4, Jacques Morel5, Laurence Macia6 and Rachel audo4, 1CHU and Univesrity of Montpellier, Montpellier, France, 2CHU Montpellier, Arles, France, 3University of Montpellier, Montpellier, France, 4CHU Montpellier, Montpellier, France, 5CHU and University of Montpellier, Montpellier, France, 6Sydney University, Brisbane, Australia

    Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…
  • Abstract Number: LB19 • ACR Convergence 2025

    Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

    Jonathan Graf1, Amy Archer2, Sergiy Kovalenko3, Katarzyna Kolossa4, John Serpa5, Tamta Kobakhidze6, Daniela Cepoi7, Andrea Everding8, Costantino Pitzalis9, Catherine Aversa2, Martin Dahl2, May Hafez2, Paul Lizzul2, Priya Raina2, Bruce Randazzo2, Yangsu Ren2, Khalil Saikali2, Cailin Sibley10, Gerd Burmester11, Jacques-eric GOTTENBERG12, Iain McInnes13, Eduardo Mysler14, Lee Simon15, Josef Smolen16, Jeffrey Sparks17, Ronald van Vollenhoven18, Michael Weinblatt19 and Paul Emery20, 1UCSF, San Francisco, California, 2AnaptysBio Inc, San Diego, California, 3Arensia Exploratory Medicine, Kyiv, Ukraine, 4MICS Centrum Medyczne, Bydgoszcz, Poland, 5Allied Biomedical Research Institute, Miami, Florida, 6Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, 7Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, 8MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, 9QMUL, Bromley Kent, United Kingdom, 10AnaptysBio Inc, San Diego, 11Charité - Universitétsmedizin Berlin, Berlin, Germany, 12Hautepierre Hospital, STRASBOURG, France, 13University of Glasgow, Glasgow, United Kingdom, 14OMI, Buenos Aires, Argentina, 15SDG LLC, West Newton, Massachusetts, 16Medical University of Vienna, Vienna, Austria, 17Brigham and Women's Hospital, Boston, Massachusetts, 18Amsterdam UMC, Amsterdam, Netherlands, 19Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, 20University of Leeds, Leeds, United Kingdom

    Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
  • Abstract Number: LB23 • ACR Convergence 2025

    A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy

    Minna Kohler1, Sally Arai2, Fawad Aslam3, Gregory Challener4, Matthew Frigault4, Melissa Griffith5, Tamiko Katsumoto6, Elena Massarotti7, Larry Moreland8, Allison Rosenthal9, Jeffrey Sparks7, Janeth Yinh4, Sarah Baxter10, Ari Bitton11, Jason Dubovsky12, Victor Yuan13, Mindy Jensen14, Andrew Clauw15, Gabrielle Furman4, Rita Gyurko7, Megan Hall9, Anna McIntyre4, Jennifer Seifert16, Emma Stainton2, Michelle Blake10, Sabrina Fox-Bosetti13, Herve Lebrec13, Amanda Pace10, Yuanyuan Xiao17, Mei-Lun Wang18, Joe Arron13 and Jeffrey Bluestone19, 1Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, 2Stanford, Palo Alto, California, 3Mayo Clinic, Arizona, Scottsdale, Arizona, 4Massachusetts General Hospital, Boston, Massachusetts, 5University of Colorado Anschutz Medical Campus, Aurora, Colorado, 6Stanford University, Millbrae, California, 7Brigham and Women's Hospital, Boston, Massachusetts, 8University of Colorado, Denver, Colorado, 9Mayo Clinic, Phoenix, Arizona, 10Sonoma Biotherapeutics, Seattle, Washington, 11Sonoma Biotherapeutics, San Diego, California, 12Sonoma Biotherapeutics, Thousand Oaks, California, 13Sonoma Biotherapeutics, South San Francisco, California, 14Sonoma Bio, Seattle, Washington, 15University of Colorado, Aurora, Colorado, 16University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, 17Sonoma Biotherapeutics, Los Altos, California, 18Sonoma Biotherapeutics, San Francisco, California, 19Sonoma Biotherapeutics Inc, South San Francisco, California

    Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
  • Abstract Number: 0463 • ACR Convergence 2025

    Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis

    Solana Cushing1, Susan Goodman2, Michael Parides1, Hadeel Abdul-Rehman1, Daniel Ramirez2, Edward DiCarlo2, Kristine Carandang3, Renee Davis4, Rebecca Blank5, Laura Donlin1, Anna Helena Jonsson6, Amit Lakhanpal2, Bella Mehta7, Dana Orange8 and Melanie smith2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 4New York, New York, NY, 5NYU Langone Health, New York, NY, 6University of Colorado School of Medicine, Aurora, CO, 7Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, 8The Rockefeller University, New York, NY

    Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
  • Abstract Number: 0447 • ACR Convergence 2025

    Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases

    Hayagrivas Manicka Bharathkumar1, Emani Srinija Reddy1, Bhaskar Pandey2, Suryansh Saini1, Sangeet Rathi1, Saransh Verma1, Chinmay Prakash Swami2, Deepak Joshi2 and Ranjan Gupta1, 1All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, Delhi, India, 2Indian Institute of Technology (IIT), Delhi, Delhi, Delhi, India

    Background/Purpose: Rheumatoid arthritis (RA) and Seronegative Spondyloarthritis (SSA), the most common types of inflammatory arthritis, have significant ankle and foot joint involvement. However, these joints…
  • Abstract Number: 0380 • ACR Convergence 2025

    Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients

    Rosa Maria Morlà Novell1, Beatriz Frade Sosa2, Maria López-Lasanta3, Meritxell Sallés Lizarzáburu4, Noemí Busquets Pérez5, Georgina Salvador Alarcón6, Marta Valls Roc7, Virginia Ruiz-Esquide8, Lola Tobalina Mastre9, Raimon Sanmartí8 and José Gomez-Puerta10, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 3Hospital Universitari Vall d´Hebron, Barcelona, Spain, 4Xarxa Sanitària Althaia Manresa, Manresa, Spain, 5Hospital de Granollers, Granollers, Spain, 6Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 7Hospital Universitari Dr Trueta, Girona, Sudan, 8Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 9IDIBAPS. Hospital Clinic de Barcelona, Barcelona, 10Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…
  • Abstract Number: 0219 • ACR Convergence 2025

    Increased Engagement With the RISE Registry Clinician Dashboard Is Associated With Improving Performance on Some but Not All Rheumatology Quality Measures

    Jing Li1, Jessica Fitzpatrick2, Jinoos Yazdany2 and gabriela Schmajuk3, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Background/Purpose: Previous studies have shown that quality measure performance tends to improve after practices join the ACR’s Rheumatology Informatics System for Effectiveness (RISE) registry, but…
  • Abstract Number: 0149 • ACR Convergence 2025

    Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis

    Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
  • Abstract Number: 0082 • ACR Convergence 2025

    IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model

    Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
  • Abstract Number: 0064 • ACR Convergence 2025

    Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice

    Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)

    Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
  • Abstract Number: 0006 • ACR Convergence 2025

    QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis

    Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
  • Abstract Number: 2639 • ACR Convergence 2025

    Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis

    VINOD GUPTA1, Adam Koller1, Benjamin Hur1, Marissa Bailey1, Kara Delger2, Elena myasoedova1, Vanessa Kronzer1, John Davis1 and Jaeyun Sung1, 1Mayo Clinic, ROCHESTER, MN, 2Mayo Clinic, St Charles, MN

    Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…
  • Abstract Number: 2288 • ACR Convergence 2025

    Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial

    Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)

    Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
  • Abstract Number: 2272 • ACR Convergence 2025

    Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort

    Francesco NATALUCCI1, Cécile VAN MULLEM1, Aleksandra AVRAMOVSKA1, Tatiana SOKOLOVA2 and Patrick Durez1, 1Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with persistent synovial inflammation. Several bDMARDs and tsDMARDs target different key players in the immune-regulatory pathways,…
  • 1
  • 2
  • 3
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology